4D Molecular Therapeutics Inc (FDMT) News

Form 8-K - Current report

4DMT Highlights Robust and Durable Clinical Activity for 4D-150 and Design of 4FRONT Phase 3 Program at 4D-150 Wet AMD Development Day

4D-150 demonstrated robust and durable clinical activity across all wet age-related macular degeneration (wet...

4DMT Announces Presentations at Upcoming Retina Conferences

EMERYVILLE, Calif., Sept. 05, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the...

4DMT to Participate in the 2024 Cantor Global Healthcare Conference

EMERYVILLE, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the...

4DMT to Host 4D-150 Wet AMD Development Day on September 18, 2024

Company to highlight 4D-150 product development strategy and Phase 1/2 PRISM clinical trial data in wet...

Form 4 - Statement of changes in beneficial ownership of securities

4DMT to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

EMERYVILLE, Calif., Aug. 12, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the...

Form 8-K - Current report

4DMT Reports Second Quarter 2024 Financial Results and Operational Highlights

Announced positive interim results from the Population Extension cohort of the Phase 2 PRISM clinical trial for...

4DMT Advances Leadership in Large Market Ophthalmology with Senior Management Hires and Formation of Ophthalmology Advisory Board

Dhaval Desai, PharmD, named as Chief Development Officer; will oversee late-stage Product Development, Medical...

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

4DMT Announces Positive Phase 2 PRISM Interim Results for Intravitreal 4D-150 in a Broad Wet AMD Population Affirming Favorable Safety Profile and Robust Clinical Activity

Robust reduction in anti-VEGF injection treatment burden through Week 24 achieved in 30 patients at planned...